Q2 FY2026 EarningsQ2 FY2026 delivered a significant beat against consensus estimates, primarily driven by $21.0M in collaboration revenue from an asset purchase agreement with Jazz Pharmaceuticals, against a $0 consensus. The company achieved a GAAP net income of $3.7M (EPS $0.08) compared to the expected net loss of -$16.7M (EPS -$0.32). While the cash position decreased to $22.0M following the full repayment of K2 HealthVentures debt, Werewolf extended its runway into Q2 2027 and is actively exploring strategic alternatives with Piper Sandler.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Werewolf Therapeutics(HOWL) the EBIT is 7.158 M (+140.8%), Beat estimate;the EPS is 0.08 (+120%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
0.01B140.80%
-0.02B7.50%
+0.02B133.30%
EPSExceed expectations
0.08120.00%
-0.3220.00%
+0.4000100.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf